Literature DB >> 25807636

Markers of endothelial activation in preeclampsia.

Martin Prochazka, Jana Procházková, Marek Lubušký, Radovan Pilka, Jana Úlehlová, Igor Michalec, Petr Polák, Marian Kacerovský, Luděk Slavik.   

Abstract

BACKGROUND: The study aimed at finding a laboratory approach to detect endothelial damage in normal pregnancy as well as in pregnancy complicated by preeclampsia using selected markers of endothelial activation. MATERIALS: A total of 403 healthy pregnant women without a history of deep vein thrombosis and/or hypertension were prospectively studied. From all women, venous blood was collected before the end of the 1st trimester, between weeks 24 and 28 of gestation, and in the 3rd trimester (weeks 34-36). Assays of tissue plasminogen activator, plasminogen activator inhibitor-1, von Willebrand factor activity and antigen, thrombomodulin, endothelial protein C receptor, and endothelial microparticles activated by TF were performed.
RESULTS: When comparing women who developed preeclampsia during pregnancy (the average levels were 23.41 μg/L, 34.33 μg/L, and 53.56 μg/L in the 1st, 2nd, and 3rd trimesters, respectively) with healthy pregnant women (the average levels were 19.05 μg/L, 28.47 μg/L, and 39.86 μg/L in the 1st, 2nd, and 3rd trimesters, respectively) significant differences in the levels of thrombomodulin were found in all three trimesters. By contrast, no statistically significant differences in the levels of vWF (both antigen and activity), t-PA, EPCR, EMPs, MMP-2, MMP-9, and TIMP-9 were found in any trimesters in the same group.
CONCLUSIONS: Pregnancy and preeclampsia strongly influence the levels of studied markers. The findings of this work confirm the possible predictive potential of thrombomodulin and PA-1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25807636

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  7 in total

1.  Clinical application of endothelial injury marker in hypertensive patients.

Authors:  Xiao Qian Guo; Wei Ren; Rui Peng; Yan Hong Liu; Yan Li
Journal:  J Clin Lab Anal       Date:  2018-03-24       Impact factor: 2.352

Review 2.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

3.  High levels of HtrA4 observed in preeclamptic circulation drastically alter endothelial gene expression and induce inflammation in human umbilical vein endothelial cells.

Authors:  Yao Wang; Guiying Nie
Journal:  Placenta       Date:  2016-09-10       Impact factor: 3.481

4.  Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia.

Authors:  Marzena Laskowska
Journal:  Biomed Res Int       Date:  2017-07-17       Impact factor: 3.411

5.  Matrix Metalloproteinases MMP-2 and MMP-9 Occupy a New Role in Severe Preeclampsia.

Authors:  Elena Timokhina; Alexander Strizhakov; Sapiyat Ibragimova; Evgeny Gitel; Irina Ignatko; Vera Belousova; Nikoleta Zafiridi
Journal:  J Pregnancy       Date:  2020-12-16

6.  Fibrinolytic Changes in Women with Preeclampsia.

Authors:  Anne Cathrine Godtfredsen; Johannes Jakobsen Sidelmann; Britta Blume Dolleris; Jan Stener Jørgensen; Emma Kathrine Jungjohan Johansen; Melissa Fernard Bøg Pedersen; Yaseelan Palarasah; Jørgen Brodersen Gram
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 7.  Endothelial Dysfunction in Pregnancy Complications.

Authors:  Jakub Kornacki; Paweł Gutaj; Anastasia Kalantarova; Rafał Sibiak; Maurycy Jankowski; Ewa Wender-Ozegowska
Journal:  Biomedicines       Date:  2021-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.